ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-ULBP2/5/6/CD3/CD2 Trispecific T-cell Engager EVOLVE104

Its studies are mostly in Urinary Bladder Neoplasms, led by EvolveImmune United.

Furthest: phase 1, since Oct 10, 20251 company-led study, 1 open or runningNext primary completion: Jan 29, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
EvolveImmune United11 open or runningphase 1since Oct 10, 2025Oct 10, 2025Jan 29, 2029phase 1 · NCT07217171

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 10, 2025First study: phase 1 study in Urinary Bladder NeoplasmsFirst studyNCT07217171 · 160 planned · United States

Ahead

  1. Jan 29, 2029Primary completion: phase 1 study in Urinary Bladder NeoplasmsNCT07217171

TargetBeta

“A trispecific T-cell engager (TCE) targeting the tumor-associated antigens (TAAs) natural-killer group 2, member D receptor protein (NKG2D or KLRK1) ligands UL16-binding protein 2, 5 and 6 (ULBP2/ULBP5/ULBP6), the T-cell surface antigen CD3, and the T-cell co-stimulatory receptor CD2, ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07217171Urinary Bladder Neoplasms · United States1RecruitingJan 29, 2029160

How it is read

Names in the registry

  • “EVOLVE104”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.